Journals / BEYOGLU EYE JOURNAL / 2020 / Cilt: 5 - Sayı: 3

Comparative Analysis of Pupil Diameters in Light and Dark Conditions After Instillation of 0.15% Brimonidine Drops in Eyes With and Without Pseudoexfoliation Syndrome

Pages
209–213
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, inadequate pupillary dilation may make it more difficult to perform cataract surgery and may further increase the complication rate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aimed to compare pupil diameters in light and dark conditions after instillation of 0.15% brimo-nidine drops in eyes with and without pseudoexfoliation syndrome (PES).Methods: Forty eyes of 40 patients in whom 0.15% brimonidine drops were instilled to their right eyes between March 2019 and June 2019 were analyzed in this study.
📊
Key Findings & Data:Study groups included 20 subjects without PES (group 1) and 20 patients with PES (group 2).
💡
Conclusion & Impact:However, inadequate pupillary dilation may make it more difficult to perform cataract surgery and may further increase the complication rate.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aimed to compare pupil diameters in light and dark conditions after instillation of 0.15% brimo-nidine drops in eyes with and without pseudoexfoliation syndrome (PES).Methods: Forty eyes of 40 patients in whom 0.15% brimonidine drops were instilled to their right eyes between March 2019 and June 2019 were analyzed in this study. Study groups included 20 subjects without PES (group 1) and 20 patients with PES (group 2). Pupil diameters before and 30 and 90 min after brimonidine application were recorded and analyzed.Results: In group 1, the mean pupil diameters before brimonidine drop instillation were 4.8±1.2 mm and 5.8±1.2 mm in light and dark conditions, respectively, while those in group 2 were 4.4±1.2 mm and 4.9±1.3 mm, respectively. At 30 min after brimonidine drop instillation, the pupil diameters in light and dark conditions were 4.3±1.1 mm and 5.3±1.0 mm in group 1 and 4.1±1.1 mm and 4.5±1 mm in group 2, respectively. In group 1, the mean pupil diameters at 90 min were 4.2±1.1 mm and 5.1±1.1 mm in light and dark, respectively, and in group 2, they were 4.0±1.1 mm and 4.4±1.2 mm, respectively. In the dark, the pupil diameters before drop instillation were significantly smaller in group 2 than in group 1 (p≤0.05). A significant difference was found between the groups with respect to the measurements in the dark at 30 min (p≤0.05). When the differences at 30 and 90 min and the initial pupil diameters in light condition were compared between the groups, the change in the pupil diameter at 30 min was statistically significant (p≤0.05). At 90 min, differences in both light and dark measurements were statistically significant (p≤0.05).Conclusion: Brimonidine causes significant miosis in eyes with PES compared with eyes without PES. Brimonidine may have positive effects on spherical aberrations, glares, and halos. However, inadequate pupillary dilation may make it more difficult to perform cataract surgery and may further increase the complication rate.

🔖

Cite This Article

CATE, S., TURGUT, B., BEKTAŞ, Ç. (2020). Comparative Analysis of Pupil Diameters in Light and Dark Conditions After Instillation of 0.15% Brimonidine Drops in Eyes With and Without Pseudoexfoliation Syndrome. BEYOGLU EYE JOURNAL, Cilt: 5 - Sayı: 3, 209–213. https://ajindex.com/articles/349116

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lindberg JG. Clinical studies of depigmentation of the pupillary margin and transil-lumination of the iris in cases of senile cataract and also in normal eyes of the aged. MD Thesis. Helsinki: Helsinki University; 1917
  2. Plateroti P, Plateroti AM, Abdolrahimzadeh S, Scuderi G. Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma: A Review of the Literature with Updates on Surgical Management. J Ophthalmol 2015;2015:370371
  3. Knight ORJ, Kaleem M, Melvani R, Bregman J, Hunter T, Couser NL, et al. Genetic abnormalities with glaucoma. In: Couser NL, editor. Ophthalmic Genetic Diseases. USA: Elsevier; 2019. p. 99–106
  4. Kivelä TT. Histopathology of Exfoliation Syndrome. J Glaucoma 2018;27:S38–S43
  5. Ritch R. Ocular Findings in Exfoliation Syndrome. J Glaucoma 2018;27:S67–S71
  6. Jeng SM, Karger RA, Hodge DO, Burke JP, Johnson DH, Good MS. The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma 2007;16:117–21
  7. Mitchell P, Wang JJ, Hourihan F. The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study. Arch Ophthalmol 1999;117:1319–24
  8. Tekin K, Sekeroglu MA, Kiziltoprak H, Yetkin E, Doguizi S, Yilmazbas P. Static and Dynamic Pupillary Characteristics in Clinically Unilateral Pseudoexfoliation Syndrome. J Glaucoma 2018;27:552–7
  9. Tekin K, Kiziltoprak H, Sekeroglu MA, Yetkin E, Bayraktar S, Yilmazbas P, et al. Static and dynamic pupil characteristics in pseudoexfoliation syndrome and glaucoma. Clin Exp Optom 2019;103:332–8
  10. Fontana L, Coassin M, Iovieno A, Moramarco A, Cimino L. Cataract surgery in patients with pseudoex-foliation syndrome: current updates. Clin Ophthalmol 2017;11:1377–83
  11. Sangal N, Chen TC. Cataract surgery in pseudoexfoliation syndrome. Semin Oph-thalmol 2014;29:403–8
  12. Repo LP, Naukkarinen A, Paljärvi L, Teräsvirta ME. Pseudoexfoliation syndrome with poorly dilating pupil: a light and electron microscopic study of the sphincter ar-ea. Graefes Arch Clin Exp Ophthalmol 1996;234:171–6. 13. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177–85
  13. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glau-coma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998;105:1960–7
  14. Ahmed FA, Hegazy K, C